3Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens, 1998,16 : 1823-1829.
4Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens, 1996,14 : 1237-1245.
6Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypcrtens, 2005,23 : 2157- 2172.
7Furukawa T, Yamakawa T, Midera T, et al. Selectivities of dihydropyridine derivatives in blocking Ca(2 + ) channel subtypes expressed in Xenopus oocytes. J Pharmaeol Exp Ther, 1999,291 : 464-473.
8Hayashi K, Wakino S, Sugano N, et al. Ca2 + channel subtypes and pharmacology in the kidney. Circ Res, 2007,100:342-353.
9Yamamoto T, Niwa S, Ohno S, et al. Structure-activity relationship study of 1, 4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg Med Chem Lett, 2006,16 : 798- 802.
10Kimura K, Suzuki N, Ohba S, et al. Effect of amlodipine, a calcium channel blocker, on rat renal arterioles, current therapeuticresearch? 1997, Curr THERAPEUTIC Resarch,58:375- 380.
